• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚洲儿童癌症研究组织当前面临的挑战代表亚洲儿科血液学和肿瘤学组。

Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group.

机构信息

Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong Children's Hospital, Hong Kong SAR, China.

Division of Pediatric Hemato Oncology & BMT, SRCC Children's Hospital Haji Ali, Mumbai, India.

出版信息

JCO Glob Oncol. 2023 Sep;9:e2300153. doi: 10.1200/GO.23.00153.

DOI:10.1200/GO.23.00153
PMID:37656946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10581612/
Abstract

In Asia, a few countries have a long and established history of collaborative clinical trials successfully formed national children's cancer study groups, but many still do not have such groups. The process of forming national children's cancer groups is fraught with many hurdles, which varies among the countries. One of the basic requirements for running clinical trials is an affordable health care system in which most of the children with cancer can receive the proposed treatment. The health insurance coverage for children with cancer varies from <20% to as high as 100% among Asian countries, and the operation of clinical trials must also be adjusted accordingly. Shortage of research personnel is common, including medical, nursing, research coordinators, and data managers. The establishment of the Asian Pediatric Hematology and Oncology Group aims to provide a good platform for promotion of international clinical trials in the Asian countries.

摘要

在亚洲,一些国家拥有悠久而成熟的合作临床试验历史,成功组建了国家儿童癌症研究组,但许多国家仍没有这样的组织。组建国家儿童癌症组织困难重重,各国情况各不相同。开展临床试验的基本要求之一是建立一个负担得起的医疗保健体系,使大多数癌症患儿能够接受所提议的治疗。亚洲各国儿童癌症患者的医疗保险覆盖率在 20%到 100%之间不等,临床试验的运作也必须相应调整。研究人员短缺很常见,包括医疗、护理、研究协调员和数据管理员。亚洲儿科血液学和肿瘤学组织的成立旨在为亚洲国家开展国际临床试验提供良好的平台。

相似文献

1
Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group.亚洲儿童癌症研究组织当前面临的挑战代表亚洲儿科血液学和肿瘤学组。
JCO Glob Oncol. 2023 Sep;9:e2300153. doi: 10.1200/GO.23.00153.
2
The U.S. pediatric cancer clinical trials programmes: international implications and the way forward.美国儿科癌症临床试验项目:国际影响与未来发展方向
Eur J Cancer. 1997 Aug;33(9):1439-47. doi: 10.1016/s0959-8049(97)00249-9.
3
Building a National Framework for Adolescent and Young Adult Hematology and Oncology and Transition from Pediatric to Adult Care: Report of the Inaugural Meeting of the "AjET" Working Group of the German Society for Pediatric Oncology and Hematology.构建青少年和青年血液学与肿瘤学国家框架以及从儿科护理向成人护理的过渡:德国儿科肿瘤学和血液学协会“AjET”工作组首次会议报告
J Adolesc Young Adult Oncol. 2017 Jun;6(2):194-199. doi: 10.1089/jayao.2016.0075. Epub 2016 Dec 16.
4
Pediatric hematology-oncology outreach for developing countries.面向发展中国家的儿科血液肿瘤学外展服务。
Hematol Oncol Clin North Am. 2001 Aug;15(4):775-87, x. doi: 10.1016/s0889-8588(05)70246-x.
5
Pediatric oncology and hematology in Birmingham, England.英国伯明翰的儿科肿瘤学与血液学
Pediatr Hematol Oncol. 1999 Jan-Feb;16(1):3-7. doi: 10.1080/088800199277542.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
POND4Kids: a global web-based database for pediatric hematology and oncology outcome evaluation and collaboration.POND4Kids:一个用于儿科血液学和肿瘤学结果评估与协作的全球网络数据库。
Stud Health Technol Inform. 2013;183:251-6.
8
Academic pediatrics in the Emma Children's Hospital, Academic Medical Center in Amsterdam (The Netherlands).荷兰阿姆斯特丹学术医疗中心艾玛儿童医院的学术儿科学。
Pediatr Hematol Oncol. 1997 May-Jun;14(3):199-203. doi: 10.3109/08880019709009489.
9
Improving outcomes for children with cancer in low-income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-Part I.改善拉丁美洲低收入国家癌症患儿的治疗效果:蒙扎国际儿科血液学/肿瘤学学院(MISPHO)近期会议报告 - 第一部分
Pediatr Blood Cancer. 2007 Mar;48(3):364-9. doi: 10.1002/pbc.21003.
10
Brief history of the Asiatic International Society of Hematology: our roots of international cooperation with Asian countries.亚洲国际血液学学会简史:我们与亚洲国家国际合作的根源。
Int J Hematol. 2018 Dec;108(6):566-570. doi: 10.1007/s12185-018-2549-5. Epub 2018 Oct 12.

引用本文的文献

1
Pediatric cancers and family financial toxicity in the Philippines: insights for Southeast Asia and similarly resourced settings.菲律宾的儿童癌症与家庭经济毒性:对东南亚及资源类似地区的启示
Lancet Reg Health West Pac. 2024 Jun 28;47:101114. doi: 10.1016/j.lanwpc.2024.101114. eCollection 2024 Jun.
2
Pediatric Oncology Hospice: A Comprehensive Review.儿科肿瘤姑息治疗:全面综述。
Am J Hosp Palliat Care. 2024 Dec;41(12):1467-1481. doi: 10.1177/10499091241227609. Epub 2024 Jan 15.

本文引用的文献

1
Treatment outcomes among high-risk neuroblastoma patients receiving non-immunotherapy regimen: Multicenter study on behalf of the Thai Pediatric Oncology Group.高危神经母细胞瘤患者接受非免疫治疗方案的治疗结果:泰国儿科肿瘤学组的多中心研究。
Pediatr Blood Cancer. 2022 Sep;69(9):e29757. doi: 10.1002/pbc.29757. Epub 2022 May 13.
2
Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage.在全球舞台上绘制儿科肿瘤临床试验协作组图谱。
JCO Glob Oncol. 2022 Feb;8:e2100266. doi: 10.1200/GO.21.00266.
3
Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India: Report by the Indian Pediatric Oncology Group (InPOG-NHL-16-01 study).印度儿童B细胞非霍奇金淋巴瘤的结局与预后因素:印度儿科肿瘤学组报告(InPOG-NHL-16-01研究)
Pediatr Hematol Oncol. 2022 Aug;39(5):391-405. doi: 10.1080/08880018.2021.2002485. Epub 2022 Jan 3.
4
Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol.采用化疗、手术和放疗联合方案对小儿高危神经母细胞瘤进行 upfront 治疗:CCCG-NB-2014 方案
Front Oncol. 2021 Nov 15;11:745794. doi: 10.3389/fonc.2021.745794. eCollection 2021.
5
Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children's Cancer Group (CCCG).中国髓母细胞瘤患儿的治疗障碍与临床结局:来自中国儿童癌症协作组(CCCG)的报告
Neurooncol Adv. 2021 Sep 17;3(1):vdab134. doi: 10.1093/noajnl/vdab134. eCollection 2021 Jan-Dec.
6
Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.长春新碱和地塞米松脉冲疗法治疗儿童急性淋巴细胞白血病(CCCG-ALL-2015):一项开放标签、多中心、随机、3 期、非劣效性试验。
Lancet Oncol. 2021 Sep;22(9):1322-1332. doi: 10.1016/S1470-2045(21)00328-4. Epub 2021 Jul 27.
7
Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group.韩国儿童急性早幼粒细胞白血病的临床特征和治疗结果:韩国儿科肿瘤研究组的一项全国性多中心回顾性研究。
Cancer Res Treat. 2022 Jan;54(1):269-276. doi: 10.4143/crt.2021.313. Epub 2021 Apr 20.
8
Collaborative cancer research: progress report from the Indian Pediatric Oncology Group.协作性癌症研究:印度儿科肿瘤学组的进展报告
Lancet Child Adolesc Health. 2021 Apr;5(4):239-240. doi: 10.1016/S2352-4642(21)00056-0.
9
Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan.台湾地区 1996 年至 2019 年儿童急性髓系白血病的治疗结果:一项回顾性分析。
Sci Rep. 2021 Mar 15;11(1):5893. doi: 10.1038/s41598-021-85321-3.
10
Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation.儿童急性淋巴细胞白血病治疗中不进行颅脑照射时的 CNS 控制的预后因素。
Blood. 2021 Jul 29;138(4):331-343. doi: 10.1182/blood.2020010438.